Comparative Pharmacology
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 210.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 210.
GASTROGRAFIN vs OMNIPAQUE 210
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastrografin is a water-soluble iodinated contrast agent that increases the radiodensity of the gastrointestinal tract, allowing visualization on X-ray. It acts by absorbing X-rays due to its high iodine content.
Radiopaque contrast agent that contains iodine, which attenuates X-rays and provides radiographic visualization of vascular structures and organs. It does not have a pharmacological mechanism of action.
Oral or rectal: 50-100 mL of a 1:1 dilution with water (or full strength as needed) for CT or fluoroscopic studies. Typically single dose.
Intravascular administration: 50-150 mL (10-30 g iodine) as bolus or infusion, based on procedure (CT, angiography, urography). Intravenous infusion for CT: 100-200 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (for absorbed diatrizoate); prolongation in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases). In neonates, half-life is 6-12 hours due to immature renal function.
Renal: 80-90% (glomerular filtration, unchanged); Biliary/Fecal: <5% (minor biliary excretion of absorbed fraction).
Renal: ~95% unchanged within 24 hours via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent